Tirzepatide, developed by Eli Lilly and Company, is positioned as a dual agonist targeting GLP-1 and GIP receptors, primarily indicated for the treatment of obesity and type 2 diabetes. The current study focuses on its pharmacokinetics in breastmilk, which could have implications for its use in lactating women. The completion of this study may enhance the product's marketability by addressing safety concerns in breastfeeding populations, potentially expanding its user base. Competitive analysis indicates that while tirzepatide faces competition from other GLP-1 receptor agonists, its unique dual-action mechanism may provide a distinct advantage. Diligence considerations should include ongoing monitoring of safety profiles and market acceptance in lactating demographics.